The present disclosure relates generally to manufacturing pharmaceutical products using additive manufacturing technology. An exemplary printing system comprises: a material supply module for receiving a set of printing materials; a flow distribution module comprising a flow distribution plate, wherein the material supply module is configured to transport a single flow corresponding to the set of printing materials to the flow distribution plate; wherein the flow distribution plate comprises a plurality of channels for dividing the single flow into a plurality of flows; a plurality of nozzles, wherein the plurality of nozzles comprises a plurality of needle-valve mechanisms; one or more controllers for controlling the plurality of needle-valve mechanisms to dispense the plurality of flows based on a plurality of nozzle-specific parameters; and a printing platform configured to receive the dispensed plurality of flows, wherein the printing platform is configured to move to form a batch of the pharmaceutical product.

An implantable medical device is provided. The device comprises a drug release layer, wherein the drug release layer comprises a naked nucleic acid dispersed within a polymer matrix. The polymer matrix includes an ethylene vinyl acetate copolymer and has a melting temperature of from about 20° C. to about 100° C. as determined in accordance with ASTM D3418-15 and a melt flow index of from about 0.2 to about 100 gram per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

The present invention aims to provide a method for producing a porous substrate containing a bioabsorbable polymer and heparin in a simple manner without use of a surfactant, a porous substrate containing a bioabsorbable polymer and heparin, and an artificial blood vessel. The present invention provides a method for producing a porous substrate containing a bioabsorbable polymer and heparin, including: a solution preparing step of preparing a heparin-bioabsorbable polymer solution having heparin uniformly dispersed therein and a bioabsorbable polymer dissolved therein, using the bioabsorbable polymer, the heparin, a solvent 1 that is a poor solvent having a lower solvency for the bioabsorbable polymer, a solvent 2 that is a good solvent having a higher solvency for the bioabsorbable polymer and is incompatible with the solvent 1, and a common solvent 3 compatible with the solvent 1 and the solvent 2; a precipitating step of cooling the heparin-bioabsorbable polymer solution to precipitate a porous body containing the bioabsorbable polymer and the heparin; and a freeze-drying step of freeze-drying the porous body containing the bioabsorbable polymer and the heparin to provide a porous substrate containing the heparin.

A method of controlling a three-dimensional (3D) bioprinter includes a nozzle end aligning operation (S100) that includes an operation (a) in which a nozzle end alignment sensor is installed at a predetermined position on a bed in a printing chamber and a sensing point of the nozzle end alignment sensor is positioned at an origin position of the bed, an operation (b) in which the bed is moved toward one side in an X-axis direction and the sensing point of the nozzle end alignment sensor is positioned under a nozzle of a first print module, an operation (c) in which the first print module is moved downward and a Z value of a nozzle end of the first print module is measured, an operation (d) in which the first print module is positioned at an original position and the bed is moved toward the other side in the X-axis direction to position the sensing point of the nozzle end alignment sensor under a syringe, which is disposed at a printing position, of a second print module, an operation (e) in which the second print module is moved downward and a Z value of a nozzle end of the syringe, which is disposed at the printing position, of the second print module is measured, and an operation (f) in which the second print module is positioned at an original position and the bed is positioned at an original position, a printing plate installing operation (S200) in which the nozzle end alignment sensor is removed, a printing plate is installed on the bed, and the printing chamber is sealed, and a printing operation (S500) in which the first print module and the second print module are controlled to perform printing on the printing plate.

A three-dimensional (3D) bioprinting method and system are disclosed. The method includes disposing/immersing a printing platform or surface into a first bioink, such as a bioink resin, curing one or more layer of the first bioink resin onto the printing platform or surface, and removing the printing platform or surface from the first bioink resin. The process is repeated with a second bioink resin such that the second bioink resin is cured on top of the one or more layer of first bioink resin, and can be further repeated with a third or even fourth bioink resin. By varying constituents of one or more or each bioink resin (such as living cell type or polymer), complex, multilayered tissues can be engineered. A system capable of performing the method is also disclosed.

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21′-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

Disclosed herein is a microneedle array comprising a substrate and a plurality of microneedles extending therefrom, wherein the microneedles comprise a biodegradable polymer and an effective amount of an analgesic or an anti-inflammatory therapeutic agent. Methods of using and making the microneedle array are also disclosed.